

Computational biomechanics at Zimmer Biomet

Philippe Favre

Research Associate Director
Computational Biomechanics



ZIMMER BIOMET
Moving You Forward.™

Agenda

Few words about Zimmer Biomet and me

The environment for medical devices

Classic use of modeling in the medical device industry

- Finite element analyses
- Anatomical analyses

Emerging applications of modeling


- In silico clinical trials



Zimmer Biomet

- 17,000 Team Members, globally
- In Switzerland: EMEA headquarter in Zug, production facility in Winterthur
- Fortune 500 company, 2024 net sales of \$7.6 billion

Joint Replacement Market Share by Company



Musculoskeletal Product and Services Portfolio

#1

Knee Arthroplasty



#1

Hip Arthroplasty



#5

Shoulder, Elbow
and Wrist Arthroplasty



Craniomaxillofacial



Thoracic



Smart Implants



Trauma



Foot and Ankle



Sports Medicine





- Allograft service
- Bone Healing
- Early Intervention & Biologics
- Surgical Products
- Oncology & Specialized Implant Solutions
- Bone Cements & Accessories
- Mixed Reality
- Robotics & Intelligent Instruments
- Care Management & Patient Engagement
- Predictive Analytics & Data Insights



Musculoskeletal Product and Services Portfolio




Few words about me



Mechanical
engineering



Biomechanics




PhD
Group leader
Clinical Biomech



Research

Comput Biomech manager




Environment in the medtech industry

Introducing a new medical device to market

Ensure safety and effectiveness of **product that will be implanted in people**

→ Important consequences if we make the wrong decisions

→ Highly regulated industry



Risk analysis

What could go wrong?



Analysis
Tests
Optimization



Mitigate the
causes of
failure



Biomechanical risks


What could go wrong?




Analysis
Tests
Optimization



Mitigate the
causes of
failure



Model input



VS



Subject created by man, we understand the complexity

Subject created by nature, we try to understand as best we can (ethically)


Sources of uncertainties

- Anatomy
- Bone quality
- In-vivo loading
- Surgery etc.





Sources of uncertainties as input


- Anatomy





- Bone quality



- In-vivo loading



- Surgery etc.



And how we deal with uncertainties

Worst case testing:
If that passes, it always will




And how we deal with uncertainties

Worst case testing:

If that passes, it always will


Standards (ISO, ASTM)

ASTM-F2996-20. Standard Practice for Finite Element Analysis (FEA) of Non-Modular Metallic Orthopaedic Hip Femoral Stems, 2020.



ASTM-F3161-16. Standard Test Method for Finite Element Analysis (FEA) of Metallic Orthopaedic Total Knee Femoral Components under Closing Conditions, 2016.

ASTM-F-3334-19. Standard Practice for Finite Element Analysis (FEA) of Metallic Orthopaedic Total Knee Tibial Components, 2019.



And how we deal with uncertainties

Worst case testing:

If that passes, it always will

Standards (ISO, ASTM)

Compare with successful implants (equivalency to predicate)

Final assessment comes only ~10 years after implantation!

New device



?


IV

Existing device with
long and good clinical
results



New product development support

Establish product safety and efficacy



The classic use of modeling at Zimmer Biomet

Typical risks that we investigate

Clinical

- Implant fracture
- Aseptic loosening
- Implant subsidence
- Bony atrophy/hypertrophy
- Intra/post OP bone fracture
- Impingement/dislocation

In silico

- Implant fatigue stress
- Micromotion and interface strain
- Permanent displacement
- Change in bone stress
- Bone ultimate/fatigue stress
- Range of motion



Adverse Event Report Form 11

Subject ID: _____ Date of Surgery: _____

Investigator ID: _____ Operative Site: _____ Form Completion Date: _____

1. Adverse Event Code (see descriptions below): _____

2. Details of Event: _____

3. Site: _____

4. Date of Onset: _____

5. Type of Event: _____

6. Severity: _____

7. Is this event related to a Zimmer device and alleges a Device Deficiency? (Yes/No) _____

8. Details of Treatment: _____

9. Outcome: _____



10. Date Reported to Your Office/Committee: _____



Worst-case identification

FEA - Finite element analysis

Significant time and financial gain





> 100 FEA simulations
of combinations



1 physical test
of worst-case






Design optimization using statistical methods



Significant time and financial gain



Enrich physical testing





Combined approach to get a better representation of primary stability


- Full micromotion distribution
- All micromotion components
- Realistic loading conditions

Impossible to do without modeling



MR interaction



Anatomical studies - virtual surgery



Database of
bone models



3D CAD models of
implants

Support new design




Persona tibial baseplate

Impractical to do without modeling!

Generate design inputs

Fit quality of the designs

Support claims



The personalized design

Tibial bone coverage

92%

with proper rotation¹

Persona Femur is able to match

97%

each patient's native A/P dimension²


Ideal tibial rotation and alignment

81.4%

in vivo³



Range of motion analysis



Patient-Matched Implants

Impractical to do without modeling!


Shoulder




Elbow





Wrist




Hip



Knee



Model validation



Benchtop test




In vitro test



In silico clinical trials ISCT

Establish product safety and efficacy




Pre clinical testing

Product
launch




Clinical follow up


Post market surveillance




Concept of in silico clinical trials (ISCT)



Technical approach



Technical approach for virtual population




45 unique anatomies



Category	Mean	SD	Min	Max
Height [m]	1.70	0.1	1.47	1.93
Weight [kg]	77.3	26.2	36.0	172.0
BMI	26.9	9.4	12.5	65.2



Technical approach for virtual population



Include surgical variability

→ Total of n=521 unique surgical interventions

45 unique anatomies





Category	Mean	SD	Min	Max
Height [m]	1.70	0.1	1.47	1.93
Weight [kg]	77.3	26.2	36.0	172.0
BMI	26.9	9.4	12.5	65.2



(PMCF: n=47 in TSA, n= 58 in hemi)



Technical approach for virtual population



Include surgical variability

→ Total of n=521 unique surgical interventions

3000 solved models

3 load cases




Category	Mean	SD	Min	Max
Height [m]	1.70	0.1	1.47	1.93
Weight [kg]	77.3	26.2	36.0	172.0
BMI	26.9	9.4	12.5	65.2



(PMCF: n=47 in TSA, n= 58 in hemi)




Humeral
loosening



Stress
shielding



Model validation strategy





Benchtop test




In vitro test



Clinical trial



ISCT model validation¹



Benchtop comparator:

- Ensure physics are modeled correctly
- Best addressed with tight control over test conditions



A risk and credibility framework for *in silico* clinical trials of medical devices

Jeffrey E. Bischoff^{a,*}, Mehul A. Dhar^a, Philippe Favre^b

^a Zimmer Biomet, 1800 West Center Street, Warsaw, IN, 46580, USA

^b Zimmer Biomet, Zählerweg 4, 6300 Zug, Switzerland



Clinical comparator:


- Ensure aspect of clinical performance, including survivorship, can be predicted appropriately
- Reproduce clinically significant differentiation in outcomes b/w different designs, variants, sizes, etc

[1] Bischoff J et al. A risk and credibility framework for *in silico* clinical trials of medical devices. Comput Methods Programs Biomed 2023



Clinical validation – Stress shielding

Comparator




Nagels et al., JSES 2003

Statistically significant increased proximal lateral humeral cortical thinning for greater relative stem size patients (N=70, Biomodular stems)

Model


N=35 bones
Biomodular stem



Sensitivity

Mesh size
Stem alignment
Stem size
Loading
Material properties

Comparison



N=188

Change in strain
energy density
→ Bone resorption

Statistically significant increased proximal lateral humeral stress-shielding for greater relative stem size patients



Regulatory uncertainty



Risk of rejection by the regulator reduced by:

- Following guidelines for clinical studies and computational modelling

[ISO 14155. Clinical investigation of medical devices for human subjects — Good clinical practice, 2011.]

[Guidance for Industry and Food and Drug Administration Staff. Reporting of Computational Modeling Studies in Medical Device Submissions, 2016.]

- Open and regular communication with the regulator
- Publish the approach



Conclusions

- Computer modeling is heavily leveraged at ZB (but it may not be representative of the orthopedic industry)
- Worst-case identification for physical testing is the standard, accepted use
- Allows us to have better implants, while having shorter and more efficient development and testing phases
- V&V work should not be underestimated, but model credibility is priceless
- Further standardization in emerging applications (ISCT) is greatly needed

